At the time of writing, Apellis Pharmaceuticals Inc [APLS] stock is trading at $22.34, up 17.58%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The APLS shares have gain 11.20% over the last week, with a monthly amount glided 25.01%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apellis Pharmaceuticals Inc [NASDAQ: APLS] stock has seen the most recent analyst activity on May 09, 2025, when Raymond James downgraded its rating to a Outperform but kept the price target unchanged to $52 for it. Previously, BofA Securities downgraded its rating to Neutral on May 09, 2025, and kept the price target unchanged to $23. On April 29, 2025, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $44 on the stock. Goldman downgraded its rating to a Neutral but stick to its price target of $36 on December 17, 2024. Morgan Stanley initiated its recommendation with a Equal-Weight and recommended $31 as its price target on November 21, 2024. RBC Capital Mkts started tracking with a Sector Perform rating for this stock on October 25, 2024, and assigned it a price target of $25. In a note dated October 16, 2024, William Blair initiated an Outperform rating.
For the past year, the stock price of Apellis Pharmaceuticals Inc fluctuated between $16.10 and $41.94. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $22.34 at the most recent close of the market. An investor can expect a potential drop of -1.52% based on the average APLS price forecast.
Analyzing the APLS fundamentals
According to Apellis Pharmaceuticals Inc [NASDAQ:APLS], the company’s sales were 754.65M for trailing twelve months, which represents an -10.61% plunge. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.26%, Pretax Profit Margin comes in at -0.3%, and Net Profit Margin reading is -0.31%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -1.16 and Total Capital is -0.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.7.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.67 points at the first support level, and at 19.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.78, and for the 2nd resistance point, it is at 25.23.
Ratios To Look Out For
It is important to note that Apellis Pharmaceuticals Inc [NASDAQ:APLS] has a current ratio of 3.77. In addition, the Quick Ratio stands at 3.16 and the Cash Ratio stands at 1.84. Considering the valuation of this stock, the price to sales ratio is 3.72, the price to book ratio is 18.04.
Transactions by insiders
Recent insider trading involved Francois Cedric, Chief Executive Officer, that happened on Jul 17 ’25 when 19725.0 shares were sold. General Counsel, Watson David O. completed a deal on Jul 16 ’25 to sell 5000.0 shares. Meanwhile, Officer Francois Cedric bought 19725.0 shares on Jul 17 ’25.
